Drugs / BGT226
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00742105 | Nov 2008 → Dec 2009 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00600275 | Dec 2007 → Mar 2010 | Cowden disease, breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGT226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00742105 ↗ |
| Known as | NVP-BGT-226 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3218578 ↗ |
| Action | Inhibit | “BGT226, an inhibitor of phosphatidylinositol 3'-kinase (PI3K)” NCT00600275 ↗1“Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3218578 ↗ |
| Modality | Small molecule | — CHEMBL3218578 ↗ |
| Route | Oral | “BGT226, Administered Orally” NCT00600275 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3218578 ↗ |